Transarterial chemoembolization, or TACE, is a catheter-based procedure that exploits a crucial vulnerability of liver tumors: they feed almost exclusively on the hepatic artery. During TACE, an interventional radiologist threads a microcatheter through the femoral artery into the vessels supplying the tumor, injects a concentrated dose of chemotherapy mixed with iodized oil, and then blocks the feeding artery with embolization particles. The technique traps high drug concentrations inside the tumor while cutting off its blood supply and sparing the rest of the body from systemic exposure. TACE has become a mainstay for primary liver cancer and an option for chemotherapy-refractory metastases, but the pharmacologic arsenal used inside the procedure has barely changed in decades, still relying on combinations of antimetabolites, antitumor antibiotics, and platinum compounds.

That stagnation is what motivated the new study. Paclitaxel, a taxane that poisons cancer cells by stabilizing their microtubules, is a cornerstone of breast cancer treatment, improving response rates and survival in both early and metastatic disease. Yet its conventional formulation requires a solvent that triggers hypersensitivity reactions and forms micelles in the bloodstream that interfere with drug delivery. Nab-paclitaxel sidesteps these problems by binding paclitaxel to human albumin nanoparticles, eliminating the solvent entirely. The albumin shell is more than a passive carrier: it exploits the cell’s natural transcytosis machinery, ferrying the drug across the tumor’s endothelial lining and boosting accumulation inside the tumor. In systemic therapy, nab-paclitaxel has outperformed solvent-based paclitaxel in metastatic breast cancer, and the landmark GeparSepto trial found nearly double the pathologic complete response rate in triple-negative patients treated with the nanoparticle formulation.

The researchers, led by Hamidreza Rouientan and Shahram Akhlaghpoor of the Pardis Noor Medical Imaging and Cancer Center in Tehran, reasoned that if nab-paclitaxel works better as an intravenous drug, it might work even better when injected directly into the tumor’s arterial supply. Their retrospective cohort study enrolled 59 patients treated for breast cancer liver metastases between June 2017 and June 2021. Thirty patients received TACE with 100 milligrams of nab-paclitaxel injected through the tumor-feeding microcatheter, immediately followed by the standard emulsion of carboplatin, mitomycin, and idarubicin mixed with iodized oil and gelatin sponge particles. Twenty-nine matched control patients underwent conventional TACE with the standard cocktail alone. All procedures were performed by a single interventional radiologist with 25 years of experience in hepatic interventions, and tumor response was assessed by an independent radiologist blinded to survival data using the RECIST 1.1 criteria.

The results on local tumor control were striking. Disease control, which combines complete response, partial response, and stable disease, was achieved in 93.3 percent of patients in the nab-paclitaxel group, compared with just 62.1 percent of those receiving conventional TACE, a difference that reached statistical significance. Most dramatic of all was the divergence in tumor progression: only 6.7 percent of nab-paclitaxel patients experienced progressive disease, versus 37.9 percent in the conventional group. The objective response rate, encompassing complete and partial responses, was 60 percent with nab-paclitaxel versus 44.8 percent with conventional TACE, and complete responses were more than three times as common in the nanoparticle group, though these latter differences did not reach statistical significance in the small sample. Multivariable analysis confirmed the pattern, showing that nab-paclitaxel significantly reduced the odds of progressive disease relative to stable disease.

Survival, however, told a more nuanced story. At the data cutoff, the overall survival rate for the entire cohort was 45.3 percent, and there were no statistically significant differences between the two treatment groups at the 6-, 12-, 18-, and 24-month marks. When the researchers applied inverse-probability weighting to adjust for confounding factors such as tumor burden, liver function, and hormone receptor status, the nab-paclitaxel group showed a mean survival advantage of 1.18 years, but the difference was not statistically significant. The study did identify one powerful prognostic factor: patients whose disease was confined to the liver had a 24-month survival rate of 60.6 percent, compared with just 30.8 percent for those with extrahepatic metastases, and liver-only disease was associated with roughly half the risk of death.

Safety findings were reassuring. No treatment-related deaths occurred, and adverse events were recorded at nearly identical rates in both groups, 50 percent after nab-paclitaxel TACE and 58.6 percent after conventional TACE. The most common complaints were abdominal pain, nausea, and fatigue, symptoms that typically lasted two to seven days and resolved with supportive care. This stands in contrast to systemic nab-paclitaxel, whose side effects include myelosuppression, alopecia, and sensory neuropathy. The authors argue that intra-arterial delivery is precisely the point: by concentrating the drug where the tumor lives, the approach achieves higher local doses with lower total drug amounts and minimal exposure of healthy tissue, potentially allowing more frequent treatment sessions than systemic chemotherapy would tolerate.

The findings fit into a broader effort to modernize the drug regimens used in liver-directed therapy. Previous studies have tested additions to the TACE cocktail, with mixed results. One German group found that adding gemcitabine to mitomycin modestly reduced progressive disease from 38.2 percent to 33 percent in breast cancer liver metastases. Other trials of gemcitabine-based TACE and doxorubicin-loaded microspheres reported disease control rates ranging from 44 to 83 percent. Against this backdrop, the 93.3 percent disease control rate and the near-elimination of progressive disease in the nab-paclitaxel group stand out, even allowing for the caveats of retrospective comparison. The authors suggest that the drug’s albumin-mediated uptake mechanism may be particularly well suited to the tumor biology that TACE creates, where embolization-induced hypoxia and the enhanced permeability of tumor vessels favor nanoparticle accumulation.

The study’s limitations are real and the authors acknowledge them candidly. The retrospective design, the single-center setting, and the modest sample size of 59 patients all constrain the strength of the conclusions, and the nab-paclitaxel group was treated as part of an evolving multidisciplinary strategy rather than a randomized protocol. Selection bias was mitigated but not eliminated by matching and statistical weighting. Larger prospective randomized trials with extended follow-up will be needed to determine whether the impressive local control translates into a survival benefit, and the authors suggest that precision medicine approaches, incorporating molecular profiling of individual tumors, may eventually identify which patients stand to gain the most from the nanoparticle formulation.

Even with those caveats, the message is provocative. For a patient population whose median survival is measured in months and whose treatment options narrow quickly after chemotherapy failure, a technique that keeps liver tumors in check with a manageable side-effect profile is not a trivial advance. The authors conclude that incorporating nab-paclitaxel into TACE could be a reasonable treatment option for breast cancer liver metastases until proven otherwise, a carefully hedged endorsement that nonetheless signals a shift: after years of relying on the same aging drug cocktails, interventional oncology may finally be ready to update its pharmacopeia, one nanoparticle at a time.

Subject of Research: Nab-paclitaxel added to transarterial chemoembolization for breast cancer liver metastases

Article Title: Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE

Article References: Nab-paclitaxel in conventional trans arterial chemoembolization for breast cancer liver metastasis: it is time to add new drugs to TACE. (n.d.). https://doi.org/10.1007/s44343-025-00006-2

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00006-2

Keywords: breast cancer, liver metastases, transarterial chemoembolization, nab-paclitaxel, interventional radiology, interventional oncology, chemotherapy, drug delivery, RECIST, tumor response, nanoparticles, locoregional therapy

The initiative, called the Think Tank HCC Meeting (TTHM), was designed by a team led by Roberto Iezzi and colleagues at Fondazione Policlinico Universitario Gemelli IRCCS in Rome, together with experts from institutions across Europe and beyond. Before the congress, 80 of 127 registered participants completed a 61-question online survey covering demographics, hospital facilities, ablation practice, transarterial chemoembolization (TACE), transarterial radioembolization (TARE), and combined treatment strategies. During the meeting itself, attendees voted anonymously through a live polling system while an expert panel, deliberately structured to simulate a multidisciplinary tumor board (MDTB), debated anonymized patient cases divided into early, intermediate, and advanced disease stages. Seventy-two, sixty-four, and seventy-eight participants voted in the three respective sessions, allowing the organizers to compare stated habits with decisions made under the pressure of a realistic clinical scenario.

The respondent pool skewed heavily toward experienced European radiologists. Roughly 82.5 percent were radiologists, of whom more than 91 percent were fully certified, and nearly 44 percent reported more than fifteen years of clinical experience. Almost 88 percent of the hospitals represented were in Europe, with nearly half of all respondents working in Italy, a detail that the authors themselves flag as a major limitation. Still, the infrastructure data were revealing: 72.5 percent of centers held a weekly multidisciplinary tumor board, 77.5 percent worked in or were networked with a transplant center, and 36.25 percent of hospitals had no access to radioembolization at all, a gap that inevitably shapes treatment choices regardless of what any algorithm recommends.

One of the most striking findings concerns thermal ablation, the recommended curative option for patients with tumors smaller than three centimeters who cannot undergo resection or transplantation. Microwave ablation has now overtaken radiofrequency ablation as the dominant technique, particularly for lesions up to four centimeters, reflecting its ability to reach higher temperatures faster and with less susceptibility to heat-sink effects near blood vessels. Yet the survey exposed a sobering quality gap: only about 36 percent of respondents systematically assessed the ablative margin, the rim of treated tissue surrounding the tumor that is widely recognized as a key predictor of local recurrence. Even more concerning, a quarter of respondents never used a multiprobe approach, and the same proportion performed ablations without any navigation system, suggesting that the technological tools available to guarantee complete tumor coverage are not being uniformly deployed.

For larger tumors, the panel showed a clear preference for combining ablation with transarterial embolization or chemoembolization rather than attempting a multiprobe ablation alone, with more than two-thirds of voters favoring the combined strategy. The technical logic is compelling: embolization can be performed in a single step alongside ablation, shortening procedural time and hospitalization, and the sequence matters. Most participants preferred to ablate first, because the hyperemic response induced by thermal injury increases drug uptake during subsequent chemoembolization, particularly in the peripheral zone of the ablation where sublethal heating may leave viable tumor cells. Post-ablation embolization also offers a safety net for patients at high risk of intraprocedural bleeding, such as those with low platelet counts or tumors in difficult locations. Cone-beam CT emerged as a pivotal adjunct in these combined procedures, improving lesion detection, identifying feeding vessels, and helping predict early treatment response.

In the intermediate-stage category, where TACE is the guideline-endorsed standard, the survey reproduced one of the field’s longest-running debates. In the pre-congress questionnaire, up to 40 percent of radiologists preferred drug-eluting bead TACE (DEB-TACE) while fewer than 20 percent favored the conventional lipiodol-based technique; during the live session, however, more than 50 percent switched their preference to conventional TACE. This inconsistency mirrors the literature itself: the PRECISION-V trial failed to demonstrate superiority of DEB-TACE over conventional TACE in overall survival, yet DEB-TACE is generally associated with lower toxicity and fewer complications. Interestingly, participants rated plain transarterial embolization as inferior to chemoembolization, even though a meta-analysis by Lawson and colleagues found comparable survival and complication rates between the two approaches, a perception the authors suggest reflects outdated habits rather than current evidence.

Perhaps the most actionable discrepancy involved balloon-occlusion microcatheters, devices that temporarily block outflow during chemoembolization to concentrate the therapeutic agent within the tumor. More than 72 percent of participants reported never using them, despite mounting evidence, including propensity-matched European multicenter analyses, that balloon-occluded TACE achieves higher complete response rates than conventional techniques. The authors argue that this represents a clear case where real-world practice lags behind the science. A similar pattern appeared with radioembolization: 36 percent of hospitals lacked access to it entirely, and although three randomized controlled trials in advanced-stage patients showed no overall survival advantage over systemic therapy, 64 percent of respondents still considered TARE more useful than systemic treatment, and many centers continue to use it in intermediate-stage patients, supported by retrospective data and by the DOSISPHERE-01 trial, which demonstrated that personalized dosimetry significantly improves response and survival compared with standard dosimetry.

The advanced-stage findings were equally revealing. BCLC guidelines recommend systemic therapy for patients with portal vein tumor thrombosis, extrahepatic spread, or declining performance status, and they do not endorse locoregional options. Yet more than half of the surveyed practitioners considered TACE feasible in these patients, a view echoed by the global BRIDGE observational study, which found that TACE is used as first-line treatment in nearly half of BCLC-C patients worldwide. The panel identified specific subgroups, such as patients with preserved liver function and peripheral tumor thrombus, so-called quasi-C patients, or those intolerant of systemic therapy, in whom degradable starch microsphere TACE, which delivers chemotherapy without ischemic injury to the compromised liver, may offer meaningful benefit. The authors caution, however, that the boundary between performance status 0 and 1 is often razor-thin, making stage classification itself a source of variability.

The overall picture that emerges is one of substantial, sometimes unjustified heterogeneity. Some deviations from the guidelines are backed by recent literature and reflect legitimate personalization, particularly as treatment migration across BCLC stages has become a de facto standard of care and multidisciplinary tumor boards increasingly override strict algorithmic allocation, in some published series with equal or superior survival outcomes. Other deviations, the authors argue, are simply outdated practices or misconceptions lacking scientific support, and clinical expertise alone should not justify divergence from evidence-based recommendations. They call for mandatory margin assessment using contrast-enhanced CT or cone-beam CT with margin-confirmation software, greater standardization of embolic agents, and continuous education to close the gap between what trials demonstrate and what physicians do.

The study’s limitations are acknowledged candidly: the sample was small, and the overwhelming European, largely Italian, composition means the results may reflect regional practice rather than a genuinely global picture. The authors also note that the reasons behind the observed heterogeneity, whether rooted in resource constraints, training traditions, or reimbursement structures, cannot be deduced from a questionnaire alone and deserve dedicated investigation at national and international meetings. Still, as a proof of concept, the Think Tank format demonstrates that live, tumor-board-style polling can surface the hidden variability of clinical practice in a way that retrospective database studies cannot. As long as each interventional radiologist follows an individual approach, the authors conclude, treatment results will remain inconsistent, complicating both patient care and the integration of locoregional procedures into universal oncological guidelines.

Subject of Research: Real-world practice of locoregional treatments for hepatocellular carcinoma compared with BCLC guideline recommendations

Article Title: Think tank on locoregional treatments in hepatocellular carcinoma: a snapshot of real-life practice

Article References: Iezzi, R., Contegiacomo, A., Posa, A., Scrofani, A. R., Rocco, B., Maresca, A., Bargellini, I., Bilhim, T., Crocetti, L., De Cobelli, F., Gasbarrini, A., Goldberg, S. N., Lucatelli, P., Muñoz, F. G., Pompili, M., & Filippiadis, D. (2025). Think tank on locoregional treatments in hepatocellular carcinoma: a snapshot of real-life practice. CVIR Oncology, 1(1), Article 15. https://doi.org/10.1007/s44343-025-00016-0

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00016-0

Keywords: hepatocellular carcinoma, interventional radiology, locoregional therapy, BCLC staging system, transarterial chemoembolization, radioembolization, microwave ablation, multidisciplinary tumor board, clinical practice guidelines, drug-eluting beads, ablative margin, liver cancer

The technique, known as irreversible electroporation, or IRE, works on an entirely different physical principle from conventional ablation. Between two and six thin needle-electrodes are placed around the tumour, and short, intense electric pulses are fired between them. The resulting electric field is strong enough to destabilise the cell membrane itself, punching nanoscale pores into the lipid bilayer. These pores allow the cell’s contents to leak out and trigger apoptosis, a form of programmed cell death, rather than the coagulative necrosis produced by burning or freezing tissue. Because the mechanism is predominantly non-thermal, the collagen scaffolding of ducts and vessels within the treated zone is largely preserved, a property that makes the technique attractive precisely where thermal energy would be most hazardous.

Crucially, IRE also sidesteps the so-called heat sink effect, the Achilles heel of radiofrequency and microwave ablation. When a tumour abuts a large blood vessel, flowing blood continuously carries heat away from the ablation zone, leaving a rim of viable tumour cells that can seed recurrence. Since IRE does not rely on raising tissue temperature, blood flow confers no such protection, and the ablation zone remains predictable even immediately adjacent to major vessels. The technique is not entirely free of thermal effects, the authors caution; temperature rises have been documented near the needle tips during long pulses at very high voltages, a detail that must inform needle placement. Still, the absence of a clinically meaningful heat sink is the central reason IRE has carved out a niche for tumours hugging the portal triad, hepatic veins, inferior vena cava, gallbladder and bowel.

In the new study, published in CVIR Oncology, researchers retrospectively analysed 56 IRE procedures performed in 54 patients at their centre between February 2014 and February 2022. All patients had solitary tumours smaller than three centimetres that a multidisciplinary team had deemed unsuitable for surgery or thermal ablation because the lesions lay within five millimetres of critical structures. The median tumour size was 22 millimetres, and the median age of patients was 61 years. Most had underlying liver disease, with hepatitis C infection and alcohol-related liver disease the most common risk factors, and all patients had well-preserved liver function, classified as Child-Pugh A. Twenty-three patients had already undergone transarterial chemoembolization for larger tumours and still harboured residual disease, while five had recurrent tumours at sites of previous thermal ablation or surgery; the remaining 26 were treatment-naive.

The procedures themselves are technically demanding. Performed under general anaesthesia with deep neuromuscular blockade to eliminate involuntary muscle contraction, they were carried out by interventional radiologists with more than a decade of ablation experience, using CT guidance to position the needles. Accurate probe parallelism, three-dimensional orientation and inter-needle spacing, maintained between 15 and 25 millimetres, are critical to success. Using the NanoKnife system, the team delivered a standard regimen of 90 pulses per electrode pair at voltages between 1000 and 1500 volts, producing currents of 20 to 40 amperes. For larger or irregularly shaped lesions, the electrodes were withdrawn by about a centimetre and a further 90 pulses delivered to extend the ablation margin, a manoeuvre performed in more than three-quarters of cases. Technical success, defined as completion of the full pulse protocol, was achieved in all 56 procedures.

The oncological results were encouraging. On the first follow-up scan four to six weeks after treatment, assessed with the modified Response Evaluation Criteria in Solid Tumours, radiologic complete response was achieved after 83.9 percent of procedures. Neither age, sex, tumour size, adjacent anatomy nor previous treatment significantly influenced the likelihood of complete response. Over a median imaging follow-up of 31.7 months, local recurrence after an initial complete response occurred in 15 of 47 procedures, or 31.9 percent. Mean local tumour progression-free survival was 41.6 months, with 91.5 percent of patients free of local progression at six months, 78.4 percent at one year and 73.7 percent at two years. Notably, outcomes were statistically indistinguishable between treatment-naive patients and those who had undergone prior locoregional therapy, suggesting IRE performs reliably regardless of tumour history.

Safety data were equally important. There were no procedure-related deaths within 30 days, and the overall complication rate was 10.7 percent, with only two major complications, both graded IIIa on the Clavien-Dindo scale: a haemothorax attributed to suspected intercostal artery injury, managed with angiography and chest drainage, and a pneumothorax treated with needle aspiration. Minor complications included transient post-ablation syndrome in two patients and asymptomatic portal vein thrombosis in two others, detected on follow-up imaging. One of these thromboses resolved fully with anticoagulation, while the other led to right lobe atrophy and secondary bile duct damage. The authors point out that although IRE is designed to spare vessels, the tissue swelling that follows treatment can compress adjacent vascular structures and promote thrombosis, and that needles should never be passed directly through vessels. Tumour seeding, a feared complication of needle-based therapies, was not observed, possibly because IRE needles bracket the tumour rather than traversing it.

The findings place IRE within a rapidly evolving therapeutic landscape. The authors note that fewer than 20 percent of patients with early-stage disease are suitable for resection, and donor shortages constrain transplantation, so percutaneous options carry disproportionate weight. Selective internal radiotherapy, in which yttrium-90 microspheres are delivered into the tumour’s arterial supply, has produced excellent results in recent trials, with the LEGACY study reporting three-year overall survival of 86.6 percent and local control above 90 percent for solitary unresectable tumours, and newer single-session workflows eliminating the need for a separate mapping angiogram. Stereotactic body radiotherapy likewise delivers local control rates of 80 to 95 percent at two to three years without requiring anaesthesia, though both alternatives involve radiation exposure, logistical complexity and cost, and both are limited by proximity to radiosensitive organs and by compromised liver function.

IRE, by contrast, demands general anaesthesia, has a genuine learning curve, takes longer than thermal ablation and uses more expensive electrodes. Bracketing a tumour with four to six parallel needles is particularly challenging for central lesions or those near the dome of the liver approached between the ribs, and the study found that tumours larger than two centimetres required significantly more needles than smaller ones. Overlapping treatments with too few needles, the authors warn, yield higher rates of incomplete ablation. These practical constraints mean the technique is best reserved for carefully selected patients: those with small tumours adjacent to bile ducts, the hepatic hilum, gallbladder, bowel or central vasculature, who are unfit for surgery but can tolerate general anaesthesia, and in whom immediate local control is the priority.

For a disease in which anatomical bad luck often forecloses curative treatment, the message from this single-centre experience is quietly significant. With complete response rates comparable to published IRE series and to thermal ablation of perivascular tumours, and safety figures in the same range as heat-based techniques despite the hostile anatomy of the treated lesions, irreversible electroporation appears to be a viable definitive option for a patient group that has long had few. The retrospective design and modest sample size mean randomised comparisons with radioembolization and stereotactic radiotherapy remain desirable, but the study suggests that for small, anatomically treacherous hepatocellular carcinomas, the answer may lie not in turning up the heat, but in switching off the heat altogether.

Subject of Research: Irreversible electroporation as a non-thermal treatment for early-stage hepatocellular carcinoma unsuitable for thermal ablation

Article Title: Irreversible electroporation as a definitive treatment for early-stage HCC unsuitable for thermal ablation: insights from a tertiary liver centre

Article References: Peddu, P., Seneviratne, N., Hashem, E., & Fang, C. (2025). Irreversible electroporation as a definitive treatment for early-stage HCC unsuitable for thermal ablation: insights from a tertiary liver centre. CVIR Oncology, 1(1), Article 17. https://doi.org/10.1007/s44343-025-00018-y

Image Credits: AI Generated

DOI: 10.1007/s44343-025-00018-y

Keywords: hepatocellular carcinoma, irreversible electroporation, thermal ablation, liver cancer, interventional radiology, heat sink effect, locoregional therapy, radiofrequency ablation, microwave ablation, transarterial chemoembolization, radioembolization, stereotactic body radiotherapy

The study, published in CVIR Oncology, draws on the CIRT registry spanning 27 sites across eight European countries and its French counterpart, CIRT-FR, which was conducted to help the French Health Authority evaluate reimbursement of yttrium-90 resin microspheres. Both registries were designed to capture real-world clinical practice rather than the tightly scripted conditions of a randomized trial, and that realism is precisely what makes the findings interesting. Physicians recorded their planned treatment intent at the start of therapy, but the researchers later reclassified each patient’s actual trajectory using predefined criteria covering transplantation, ablation, resection, or a sustained complete response lasting at least one year as measured by modified RECIST criteria.

The headline numbers tell a story about the gap between intention and outcome. Although 229 of the 615 patients, roughly 37 percent, were initially slated for curative-intent treatment pathways, only 40 patients, or 6.5 percent, ultimately met the retrospective curative-intent definition, while 93 percent were classified as palliative. Of those 40, half went on to liver transplantation after TARE, seven received ablation and two underwent resection. Most remarkably, 11 patients, 27.5 percent of the curative group, required no further treatment at all because TARE alone had produced a complete tumor response documented for at least a year.

That last figure carries particular weight given how the authors framed their expectations. Among 32 patients whose a priori plan was radiation segmentectomy, meaning planned curative yttrium-90 monotherapy, only one ultimately achieved a curative classification through subsequent transplantation. In other words, the patients who ended up cured by radiation alone were rarely the ones selected for that purpose in advance. Their complete responses were, in a sense, discovered rather than engineered, which the authors say underscores how little consensus currently exists on who will convert to a curative pathway after radioembolization and how urgently refined conversion criteria are needed.

The statistical analysis offers some clues. In multivariable logistic regression, three factors independently predicted placement in the curative-intent group: an ECOG performance status of zero, corresponding to fully active patients, carried an odds ratio of 0.44; having one to three tumors yielded an odds ratio of 0.39; and a total tumor volume below 150 cubic centimeters produced an odds ratio of 0.40. That 150 cubic centimeter threshold emerged from receiver operating characteristic analysis as one of two optimal cut points for separating curative from palliative patients, and it was selected for its higher specificity of 0.725. Notably, 72.5 percent of curatively treated patients fell below this volume, which is substantially larger than the roughly 65 cubic centimeter ceiling imposed by the classic Milan criteria for transplantation eligibility.

This discrepancy is central to the paper’s argument. The Milan criteria, which have governed transplant selection for hepatocellular carcinoma for nearly three decades, rest almost entirely on morphometric measurements, and the authors found no significant differences between their curative and palliative groups on Milan-based eligibility before treatment. Around 80 percent of the curatively managed patients were outside Milan criteria before TARE. The implication is that radioembolization can shrink tumors enough to pull patients back within transplant boundaries, and that tumor volume thresholds well beyond Milan’s limits, combined with biological markers such as alpha-fetoprotein and the ALBI grade of liver function, may better identify who stands to benefit. The authors point to emerging tools like the Metroticket 2.0 model as the kind of finer-grained metrics the field needs.

Dosimetry adds another technical layer to the story. Because absorbed radiation doses were not prospectively collected in the original registries, the team recalculated them retrospectively using the simplified Medical Internal Radiation Dose formula, dividing administered activity by tumor mass. Their surrogate analysis found that absorbed doses above 400 grays correlated with longer survival, a threshold repeatedly associated with complete response in prior literature. Crucially, 92.3 percent of patients who received doses above that level had tumors under 150 cubic centimeters, suggesting that the concentration of radiation achievable in smaller, more selectively targeted volumes is what drives these dramatic responses. Yet the data also showed that doses exceeding 400 grays remained effective in tumors up to about 150 cubic centimeters, roughly 6.6 centimeters in diameter, larger than many earlier studies had considered treatable at such intensities.

Survival outcomes reinforce the signal. Median overall survival was not reached in the complete response, resection, and ablation subgroups by the end of follow-up, and in the transplantation subgroup, 75 percent and 85 percent survival percentiles were reached at 37.1 and 11.4 months respectively, with only one death recorded in the resection and ablation group and none in the complete response group. By contrast, the palliative group’s median survival of 16.1 months compares favorably with the 8.0 and 8.8 months reported in the landmark SARAH and SIRveNIB randomized trials of radioembolization versus sorafenib in advanced disease, and aligns with more recent prospective figures of 13.9 months. The real-world palliative performance alone is notable, but the theoretical cure fractions achieved in a minority of patients are what will spark debate.

The authors are careful about the limits of their evidence. This was an exploratory, retrospective classification layered onto prospective observational data, with no harmonized definition of curative intent when the studies began. Baseline characteristics were collected only before TARE, alpha-fetoprotein levels were missing in more than a fifth of curative patients and more than 40 percent of palliative patients, and dosimetry relied on a surrogate calculation. The heterogeneity of post-TARE curative procedures across different national practices further complicates generalization. Still, the conclusion is clear and consequential: yttrium-90 radioembolization belongs not just in the palliative toolbox but across the full spectrum of curative-intent strategies for hepatocellular carcinoma, whether as a bridge to transplantation, a downstaging tool before resection or ablation, or, in carefully selected patients with small tumor burdens and good performance status, as a standalone therapy capable of eradicating the disease outright. The task now facing the field, the authors argue, is to marry morphometry, tumor biology, and personalized dosimetry into reliable criteria that can identify, before the first microsphere is injected, which patients will be among the lucky few whose cancer never returns.

Subject of Research: Curative-intent transarterial radioembolization with yttrium-90 in hepatocellular carcinoma

Article Title: Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies

Article References: Helmberger, T., Arnold, D., Loffroy, R., Ronot, M., Sangro, B., Kolligs, F., Pellerin, O., Maleux, G., Peynircioglu, B., Schaefer, N., Bilbao, J. I., de Jong, N., Geyer, M., Zeka, B., Urdaniz, M., & Vilgrain, V. (2026). Hepatocellular carcinoma patients treated with TARE monotherapy or combination therapy with curative intent: a retrospective, exploratory analysis of two European prospective studies. CVIR Oncology, 2(1), Article 5. https://doi.org/10.1007/s44343-026-00035-5

Image Credits: AI Generated

DOI: 10.1007/s44343-026-00035-5

Keywords: hepatocellular carcinoma, TARE, yttrium-90, radioembolization, liver transplantation, radiation segmentectomy, Milan criteria, dosimetry, tumor downstaging, locoregional therapy, complete response, CIRT registry

The TKI era delivered incremental but real gains. Lenvatinib emerged as a non-inferior first-line alternative to sorafenib, while regorafenib, cabozantinib, and the anti-VEGFR-2 antibody ramucirumab — the latter reserved for patients with alpha-fetoprotein levels of at least 400 ng/mL — extended survival after sorafenib failure. Yet the ceiling was low: median life expectancy on first-line TKI therapy rarely exceeded 12 to 13 months. Progressive liver dysfunction, clinical decompensation, and the difficulty of tolerating TKIs long-term exposed a fundamental limitation. Immune checkpoint inhibitors (ICIs) tested as monotherapy also failed to beat sorafenib in phase III studies, leaving the field at an impasse until combination immunotherapy arrived.

The turning point came with regimens that pair PD-1 pathway blockade with either VEGF inhibition or CTLA-4 inhibition. Median overall survival for untreated advanced HCC patients, once roughly six months, climbed to between 16 and 23 months in contemporary phase III trials — a leap accompanied by higher response rates, better safety profiles, and improved quality of life. Four pivotal trials now define first-line care. IMbrave150 showed atezolizumab plus bevacizumab (A + B) achieved a median overall survival of 19.2 months versus 13.4 months for sorafenib, with an objective response rate of 30% versus 11%, though six grade 5 bleeding events in the combination arm underscored the need for baseline endoscopic varices screening. HIMALAYA demonstrated that a single priming dose of tremelimumab plus monthly durvalumab (the STRIDE regimen) improved median survival to 16.4 months, with striking five-year survival of 19.6% compared with 9.4% for sorafenib.

CheckMate 9DW added a third option, combining ipilimumab induction with nivolumab maintenance against a control arm dominated by lenvatinib. Median overall survival reached 23.7 months versus 20.6 months, with a 36% response rate and a 48-month survival rate of 31% versus 18%. Notably, early deaths from hepatic events caused the survival curves to cross within the first six months, a reminder that close monitoring for liver decompensation is essential. The fourth positive trial, CARES-310, paired camrelizumab with the TKI rivoceranib and achieved the highest hazard ratio benefit (0.64) and a 23.8-month median survival — but with grade 3–4 toxicity in 81% of patients and a predominantly Asian, hepatitis B-driven population, its results are difficult to extrapolate to Europe, where alcohol-related liver disease, hepatitis C, and metabolic dysfunction-associated steatohepatitis (MASH) predominate.

Underlying liver disease aetiology was once thought to blunt immunotherapy efficacy, particularly in MASH-related HCC, but subsequent analyses have been inconsistent, and current European Society for Medical Oncology (ESMO) guidelines recommend the approved regimens regardless of aetiology. A thornier question concerns patients with Child-Pugh B liver dysfunction, who were largely excluded from phase III trials. Evidence from CheckMate 040 cohort 5 — where nivolumab achieved a 12% response rate and 7.6-month median survival in 49 Child-Pugh B7–B8 patients — and from a meta-analysis of 22 studies suggests immunotherapy is not absolutely contraindicated, though survival is markedly worse than in patients with preserved liver function. The authors stress that the cause of hepatic decline, whether tumour burden or decompensated cirrhosis, must be weighed case by case, ideally with refined tools such as the ALBI grade and within multidisciplinary team consensus.

Managing immune-related liver injury has itself become a core clinical skill. Because HCC arises on a backdrop of chronic liver disease, immune-mediated hepatotoxicity occurs earlier and more frequently than in other solid tumours, and diagnosis is complicated by the absence of specific criteria and by baseline liver test abnormalities. Most cases resolve without permanent discontinuation, but fatal hepatic toxicities have been reported, making vigilant monitoring and early multidisciplinary involvement non-negotiable elements of modern care.

What happens after first-line immunotherapy fails remains one of the field’s largest unmet needs. ESMO guidelines recommend only TKIs — sorafenib, lenvatinib, regorafenib, or cabozantinib — or ramucirumab in the second line, regardless of prior immunotherapy exposure. Observational data from the European LEVIATHAN registry favour lenvatinib over sorafenib after A + B failure (progression-free survival of 5.5 versus 2.6 months), and single-arm Asian phase II trials support regorafenib and cabozantinib in this setting. The recent IMbrave251 trial, though negative for its primary endpoint, provided the first randomised phase III benchmark for TKI monotherapy after first-line immunotherapy: 12.5-month overall survival and 4.8-month progression-free survival in the TKI-only arm. Crucially, no immunotherapy agent holds European approval in the second line — a stark contrast with the United States, where pembrolizumab and ipilimumab plus nivolumab are licensed after TKI failure. Off-label immunotherapy use in Europe therefore depends on institutional policies and is often not reimbursed, pushing costs onto hospital budgets, insurers, or patients themselves.

Access inequity emerges as the review’s most provocative theme. Although the European Medicines Agency grants EU-wide marketing authorisation, national reimbursement decisions vary enormously. Atezolizumab plus bevacizumab and the STRIDE regimen are now reimbursed in 23 and 18 European countries respectively, but ipilimumab plus nivolumab — EMA-approved in March 2025 — was, more than a year later, reimbursed in only one country, Germany. During 2016–2021, compliance with the EU’s recommended 180-day reimbursement deadline ranged from 100% in Germany to just 3% in Belgium. Molecular profiling offers little help in personalising choices: no genomic alteration in HCC reaches the top tiers of the ESMO ESCAT framework, and in the French Genomic Programme only 3 of 135 HCC patients were successfully matched to a targeted therapy. Emerging predictors — tumour immune contexture signatures, the CRAFITY score combining AFP and C-reactive protein, radiomic machine-learning models, and gut microbiome profiles — show promise but await prospective validation.

Meanwhile, European practice is quietly diverging from guidelines in the locoregional arena. Trans-arterial chemoembolization remains the standard for liver-confined intermediate-stage disease, and phase II/III trials including EMERALD-1 and LEAP-012 have shown progression-free survival gains from adding PD-1/PD-L1 blockade to TACE — though no overall survival benefit has yet been demonstrated and no European marketing authorisation exists for the combination. Selective internal radiotherapy (SIRT) with yttrium-90 microspheres, once dismissed after the negative SARAH and SIRveNIB trials, has been rehabilitated by the DOSISPHERE-01 study, which showed that personalised dosimetry delivering at least 205 Gy to the tumour significantly improves survival, even in patients with portal vein thrombosis. The prospective French PROACTIF registry of 989 patients reported 21.8-month median survival after SIRT, yet no randomised comparison with immunotherapy exists, leaving a widening gap between routine practice and guideline-endorsed standards.

The authors call for a coordinated, multi-stakeholder response: harmonised reimbursement pathways, prospective evidence for treatment sequencing, validated predictive biomarkers, broader access to clinical trials beyond academic centres through platforms such as the EU’s Clinical Trials Information System, and universal multidisciplinary review — potentially expanded through virtual networks supported by artificial intelligence. With HCC ranking thirteenth by incidence and sixth by mortality in Europe, the science has finally delivered survival gains once thought impossible. The remaining challenge, the review concludes, is no longer inventing effective treatments but ensuring that every European patient can actually receive them.

Subject of Research: Systemic and locoregional treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article Title: Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe

Article References: Pinato, D. J., Alimenti, E., Lombardi, P., Vaz, J., Digklia, A., Edeline, J., Ben Khaled, N., Di Giacomo, E., Scheiner, B., Ramos, J. P., O’Kane, G. M., Cappuyns, S., Tesini, G., & Rimassa, L. (2026). Systemic treatment paradigms for unresectable and advanced hepatocellular carcinoma in Europe. The Lancet Regional Health – Europe, 70, Article 101839. https://doi.org/10.1016/j.lanepe.2026.101839

Image Credits: AI Generated

DOI: 10.1016/j.lanepe.2026.101839

Keywords: hepatocellular carcinoma, immunotherapy, atezolizumab, bevacizumab, durvalumab, tremelimumab, tyrosine kinase inhibitors, EMA, reimbursement, health inequality, locoregional therapy, biomarkers